Alliance A021806 (Pancreatic Cancer)

What is the Purpose of this Study?

If you join this study, you will:
- Be randomly assigned (a fair 50/50 chance) to 1 of 2 treatment groups
-- One group will be treated with FOLFIRINOX chemotherapy for about 4 months, then have surgery, and receive FOLFIRINOX for about 2 months after surgery
-- The other group will have surgery first and then be treated with FOLFIRINOX for about 6 months after surgery
- Return to the clinic every 4 months for about 2 years after treatment is finished
- Receive phone calls every 6 months for about 6 years after treatment is finished

What is the Condition Being Studied?
Newly diagnosed pancreatic cancer

Who Can Participate in this Study?

Adults with pancreatic cancer who have not received treatment yet.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out if it is better to give chemotherapy before or after surgery for pancreatic cancer. We want to know which approach gives people the best chance at a good outcome.

Study Details

Full Title
Alliance A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Principal Investigator
Jeffrey Crawford
George Barth Geller Distinguished Professor for Research in Cancer

Contacts
Gastrointestinal Oncology DCI Clinical Research Team
Protocol Number
IRB:
PRO00107486

NCT:
NCT04340141
ClinicalTrials.gov
View on ClinicalTrials.gov